Ascletis Pharma Inc (2VJ) - Net Assets

Latest as of December 2025: €1.93 Billion EUR ≈ $2.26 Billion USD

Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has net assets worth €1.93 Billion EUR (≈ $2.26 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.07 Billion ≈ $2.42 Billion USD) and total liabilities (€132.26 Million ≈ $154.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 2VJ tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets €1.93 Billion
% of Total Assets 93.6%
Annual Growth Rate 18.84%
5-Year Change -29.12%
10-Year Change N/A
Growth Volatility 97.69

Ascletis Pharma Inc - Net Assets Trend (2016–2025)

This chart illustrates how Ascletis Pharma Inc's net assets have evolved over time, based on quarterly financial data. See 2VJ defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Ascletis Pharma Inc (2016–2025)

The table below shows the annual net assets of Ascletis Pharma Inc from 2016 to 2025. For live valuation and market cap data, see 2VJ company net worth.

Year Net Assets Change
2025-12-31 €1.93 Billion
≈ $2.26 Billion		 -1.62%
2024-12-31 €1.97 Billion
≈ $2.30 Billion		 -16.05%
2023-12-31 €2.34 Billion
≈ $2.74 Billion		 -7.79%
2022-12-31 €2.54 Billion
≈ $2.97 Billion		 -6.93%
2021-12-31 €2.73 Billion
≈ $3.19 Billion		 -8.47%
2020-12-31 €2.98 Billion
≈ $3.49 Billion		 -10.31%
2019-12-31 €3.32 Billion
≈ $3.89 Billion		 -3.01%
2018-12-31 €3.43 Billion
≈ $4.01 Billion		 +294.03%
2017-12-31 €869.83 Million
≈ $1.02 Billion		 +112.63%
2016-12-31 €409.08 Million
≈ $478.26 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Ascletis Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 174360900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components €3.77 Billion 194.88%
Total Equity €1.93 Billion 100.00%

Ascletis Pharma Inc Competitors by Market Cap

The table below lists competitors of Ascletis Pharma Inc ranked by their market capitalization.

Company Market Cap
Yunnan Salt & Salt Chemical Industry Co Ltd
SHE:002053
 $1.32 Billion
Wuxi Zhenhua Auto Parts Co. Ltd.
SHG:605319
 $1.32 Billion
UTI Asset Management Company Limited
NSE:UTIAMC
 $1.32 Billion
SEAZEN GROUP LTD. HD-001
F:6FLA
 $1.32 Billion
Lightspeed Commerce Inc
TO:LSPD
 $1.32 Billion
Ningbo Exciton Technology Co Ltd
SHE:300566
 $1.32 Billion
Wacker Neuson SE
F:WAC
 $1.32 Billion
IRSA Inversiones Y Representaciones
NYSE:IRS
 $1.32 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ascletis Pharma Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,966,162,000 to 1,934,264,000, a change of -31,898,000 (-1.6%).
  • Net loss of 359,880,000 reduced equity.
  • Share repurchases of 81,578,000 reduced equity.
  • New share issuances of 433,427,000 increased equity.
  • Other factors decreased equity by 23,867,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €-359.88 Million -18.61%
Share Repurchases €81.58 Million -4.22%
Share Issuances €433.43 Million +22.41%
Other Changes €-23.87 Million -1.23%
Total Change €- -1.62%

Book Value vs Market Value Analysis

This analysis compares Ascletis Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.55x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 2.01x to 0.55x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €0.53 €1.07 x
2018-12-31 €3.06 €1.07 x
2019-12-31 €3.00 €1.07 x
2020-12-31 €2.71 €1.07 x
2021-12-31 €2.51 €1.07 x
2022-12-31 €2.34 €1.07 x
2023-12-31 €2.25 €1.07 x
2024-12-31 €2.04 €1.07 x
2025-12-31 €1.96 €1.07 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ascletis Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -18.61%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -17745.56%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.07x
  • Recent ROE (-18.61%) is below the historical average (-8.88%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 -9.84% -81.29% 0.06x 1.97x €-54.04 Million
2017 -9.03% -101.38% 0.05x 1.66x €-113.63 Million
2018 -0.21% -4.36% 0.05x 1.03x €-350.00 Million
2019 -2.89% -55.33% 0.05x 1.03x €-428.39 Million
2020 -7.02% -597.81% 0.01x 1.03x €-507.41 Million
2021 -7.29% -258.88% 0.03x 1.04x €-471.92 Million
2022 -12.40% -582.07% 0.02x 1.05x €-568.83 Million
2023 -6.18% -255.70% 0.02x 1.06x €-378.92 Million
2024 -15.31% -23455.65% 0.00x 1.08x €-497.55 Million
2025 -18.61% -17745.56% 0.00x 1.07x €-553.31 Million

Industry Comparison

This section compares Ascletis Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $2,587,335,592
  • Average return on equity (ROE) among peers: -46.41%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Ascletis Pharma Inc (2VJ) €1.93 Billion -9.84% 0.07x $1.32 Billion
PROQR THERAPEUTICS EO-04 (0PQ) $113.23 Million -53.64% 0.85x $142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP) $3.94 Million -301.40% 1.87x $141.34 Million
Theravance Biopharma Inc (0TB) $350.23 Million -54.44% 0.83x $828.57 Million
I-MAB SPONS.ADS/1 -0001 (0VY) $201.16 Million -11.05% 0.06x $173.06 Million
PreveCeutical Medical Inc (18H) $-296.06K 0.00% 0.00x $3.34 Million
Argen-X (1AE) $4.10 Billion -7.20% 0.11x $41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5) $209.51 Million -46.30% 0.68x $1.14 Billion
BIOCURE TECHNOLOGY INC. (1WH) $1.58 Million -6.53% 0.28x $960.84K
ZAI LAB LTD0000006 (1ZLB) $840.90 Million -30.57% 0.41x $1.82 Billion
BioNTech SE (22UA) $20.06 Billion 47.04% 0.16x $20.05 Billion

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology
Market Cap
$1.32 Billion
€1.13 Billion EUR
Market Cap Rank
#7882 Global
#1051 in Germany
Share Price
€1.07
Change (1 day)
+0.00%
52-Week Range
€0.90 - €1.99
All Time High
€1.99
Categories
Companies in Germany Biotechnology
About

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more